Join our daily newsletter At The Bell to receive exclusive market insights
- Singular Health Group (SHG) has concluded its Cranial Implant Design project
- Having developed and integrated an artificial intelligence model capable of automatically generating a cranial implant within four minutes with a 91 per cent level of accuracy, SHG says it’s setting its sights on a collaboration with Osteopore to validate the model and seek US FDA and Australia TGA certification
- The company says it looks forward to working closely with Osteopore to develop a commercial outcome for both companies
- Singular Health Group is up 2.44 per cent, trading at 21 cents, while Osteopore is up 2.78 per cent, trading at 18.5 cents
Singular Health Group (SHG), in collaboration with Australia’s national science agency, CSIRO, has concluded its Cranial Implant Design project.
Having developed and integrated an artificial intelligence model capable of automatically generating a cranial implant within four minutes with a 91 per cent level of accuracy, SHG said it’s setting its sights on a collaboration with Osteopore (OSX) to validate the model and seek US FDA and Australia TGA certification.
Osteopore is considered a global leader in the manufacture of innovative regenerative implants at a commercial scale. In collaboration with clinicians and researchers, Osteopore develops implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs.
SHG previously completed its AI model which was configured to use standard DICOM inputs to work across both Windows and MacOS hardware, and to output the generated cranial implant design into the Company’s 3Dicom Surgical software.
The project was made possible by CSIRO Kick-Start, which provides funding and support for Australian start-ups and small businesses to access CSIRO’s research expertise and capabilities to help grow and develop their business.
Whilst in 3Dicom Surgical, the cranial implant can be edited in either the 2D or 3D views by a surgeon or bioengineer to make patient specific edits and increase the accuracy to nearly 100 per cent.
The main objective of SHG’s new project with Osteopore would be to collate empirical data to develop a pathway to full FDA approval for the AI model and deployment for use with Osteopore’s cutting-edge bioresorbable material.
“I have to highly commend the innovative development and work ethic of the CSIRO team,” said Singular Health Chief Executive Officer Thomas Hanly.
“This best-in-class model, compared to the 2021 AutoImplant Grand Challenge, really demonstrates the ability of AI to accelerate the manual processes in the Scan to Surgery workflow.
“I now look forward to working closely with Osteopore to develop a commercial outcome for both companies.”
Singular Health Group was up 2.44 per cent, trading at 21 cents, while Osteopore was up 2.78 per cent, trading at 18.5 cents.
